1. Australia Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Medical Developments International Limited

Medical Developments International Limited

MVP.AX
Medical Developments International LimitedAU flagAustralian Securities Exchange
0.43
AUD
+0.01
- -
47.88MMarket Cap
Medical Developments International Limited
MVP.AX
(Australian Securities Exchange)

Recent

price

0.43

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.15
0.19
0.2
0.2
0.16
0.19
0.24
0.27
0.28
0.31
0.33
0.35
0.3
0.37
0.37
0.36
Revenue per Share
0.02
0.03
0.05
0.04
0.01
0.03
0.03
0.03
- -
0.02
0.01
-0.18
-0.17
-0.06
-0.46
- -
Basic EPS, GAAP
-0.01
-0.02
-0.04
-0.05
-0.03
-0.03
-0.07
-0.14
-0.17
-0.15
-0.13
-0.09
-0.07
-0.09
-0.04
-0.01
Free Cash Flow per Basic Share
- -
- -
0.02
0.04
0.01
- -
0.01
0.02
0.02
0.03
0.03
- -
- -
- -
- -
- -
Dividend per Share
0.23
0.27
0.29
0.27
0.26
0.29
0.31
0.35
0.33
0.64
0.6
0.91
0.71
0.87
0.48
0.47
Book Value per Share
0.07
0.09
0.08
0.02
- -
0.02
-0.03
-0.04
-0.17
0.09
-0.02
0.41
0.22
0.5
0.26
0.3
Tangible Book Value per Share
54
54
56
59
60
60
60
61
62
67
68
71
74
87
89
110
Basic Weighted Avg Shares
8
10
11
12
9
12
14
16
17
21
23
25
22
32
33
39
Sales/Revenue/Turnover
10.4
18.45
28.19
24.4
4.61
15.2
0.76
-4.72
-7.69
-5.23
-11.08
-38.47
-68.26
-63.55
-50.88
-4.51
Operating Margin (%)
- -
- -
- -
- -
- -
- -
1
1
2
2
3
4
3
3
3
3
Depreciation Expense
1
2
3
2
1
2
2
2
- -
1
- -
-13
-12
-6
-41
- -
Net Income, GAAP
30.95
30.14
28.64
27.66
- -
29.73
31.81
26.11
19.27
33.08
- -
- -
- -
- -
- -
44.05
Effective Tax Rate (%)
10.6
17.08
23.9
19.68
9.34
13.17
10.92
11.07
1.39
4.97
1.68
-49.72
-55.47
-17.44
-123.66
0.24
Profit Margin (%)
3
4
5
2
1
3
7
5
3
27
18
40
24
27
17
28
Working Capital
- -
- -
- -
- -
1
1
- -
- -
9
- -
3
3
2
2
2
2
LT Debt
13
14
16
16
16
17
19
22
21
45
43
68
57
81
46
55
Total Equity
4.78
9.48
14.5
12.29
- -
6.47
0.35
-2.51
-4.14
-1.9
- -
- -
- -
- -
- -
-1.87
Return on Invested Capital (%)
7.29
13.03
17.84
13.88
- -
8.26
8.35
8.9
1.39
2.98
- -
- -
- -
- -
- -
0.27
Return on Capital (%)
7.28
13.03
17.84
14.51
5.54
9.2
8.68
9.08
1.17
3.27
0.9
-23.68
-21.17
-8.76
-69.22
0.2
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.95%
12.03%
20.49%
Free Cash Flow
16.35%
-25.13%
-67.18%
Net Income, GAAP
-274.51%
-588.15%
-100.23%
Sales/Revenue/Turnover
13.73%
13.07%
17.82%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
32
2024
- -
- -
- -
- -
33
2025
- -
- -
- -
- -
39

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.06
2024
- -
- -
- -
- -
-0.46
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Laurus Labs Limited (LAURUSLABS.BO)
Syntara Limited (SNT.AX)
MGC Pharmaceuticals Limited (MXC.AX)
Nippon Chemiphar Co., Ltd. (4539.T)
Haemato AG (HAEK.DE)
Aequus Pharmaceuticals Inc. (AQSZF)
Business
Medical Developments International Limited (ASX:MVP) manufactures and distributes specialised healthcare products focused on acute pain management and respiratory care. The company offers Penthrox, a non-opioid inhaled analgesic for trauma, emergency, and procedural pain relief delivered via a green whistle device; a range of respiratory devices including spacers and nebulisers such as the Breath-A-Tech brand to manage asthma and chronic obstructive pulmonary disease (COPD); and veterinary equipment for animal care. These products serve hospitals, ambulance services, sports medicine, general practitioners, and veterinary professionals. Founded in 1971 and headquartered in Scoresby, Victoria, Australia, Medical Developments International Limited operates globally with products registered in over 28 countries across Australia, Asia, Europe, and the United States. The company maintains state-of-the-art manufacturing facilities in Scoresby and emphasises innovation through partnerships like those with Australia's CSIRO. Recent developments include a strategic partnership with Labatec Pharma SA to enhance Penthrox commercialisation and market access in Switzerland, supporting a transition to a partner-supported operating model; signals at the 2025 AGM of accelerated volume growth for Penthrox through deeper partner engagement, publication of MAGPIE paediatric trial data, new health-economic analyses, and increased investment in commercial and medical affairs particularly in Australia; ongoing US respiratory market expansion; and a director's market acquisition of 62,858 ordinary shares in September 2025 reflecting internal confidence. Revenue reached $33.2 million in FY24, with FY25 sales at $39.1 million and a return to positive net profit.